Chimerix (Chimerix) Forward Dividend Yield % : 0.00% (As of May. 24, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chimerix Forward Dividend Yield %?

As of today (2024-05-24), the Forward Annual Dividend Yield of Chimerix is 0.00%.

As of today (2024-05-24), the Trailing Annual Dividend Yield of Chimerix is 0.00%.

CMRX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.585
* Ranked among companies with meaningful Forward Dividend Yield % only.

Chimerix's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Chimerix's Forward Dividend Yield %

For the Biotechnology subindustry, Chimerix's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimerix's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Chimerix's Forward Dividend Yield % falls into.

Chimerix Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Chimerix (NAS:CMRX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Chimerix Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Chimerix's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimerix (Chimerix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

CXF:Germany CXF:Germany

Address

2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713

Website

https://www.chimerix.com

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Executives

Fred A Middleton	director	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
David Jakeman	officer: Principal Accounting Officer	C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael A. Sherman	director, officer: Chief Executive Officer	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Michael T. Andriole	officer: Chief Business Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Cantex Pharmaceuticals, Inc.	10 percent owner	1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed	officer: Chief Medical Officer	C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols	officer: Chief Medical Officer	C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz	officer: Principal Executive Officer	2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey	officer: Chief Medical Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713